The phase III TRUSTY trial is currently underway to confirm the non-inferiority of TFTD plus Bmab to S-1 plus irinotecan/FOLFIRI plus Bmab in patients with unresectable refractory colorectal cancer and those who are intolerant to first-line fluoropyrimidines, OX, Bmab, and anti-EGFR antibodies. Here, EGFR is linked to colorectal cancer.